Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Musculoskeletal | Rheumatology | Nephrology | Family Medicine
 Disease Category: Gout (Hyperuricemia)
Location: United States, MD

Trial Information

A multicenter, randomized, active-controlled , Phase 3B study to evaluate the Cardiovascular safety of Febuxostat (ULORIC) and Allopurinol in subjects with Gout and Cardiovascular Comorbidities

Do you have Gout? You may qualify to participate in a clinical research study.

Cardiovascular Outcomes in gouty arthritis
There are ongoing concerns for the potential of gouty arthritis patients to have a higher risk of adverse cardiovascular events. This trial is seeking gouty arthritis patients with defined cardiovascular events or diabetes who are at high risk for cardiovascular events defined as diabetic patients with microvascular or macrovascular disease. Patients will be randomized to febuxostat (Uloric), in two doses, as well as allopurinol. There will be 5 years of ongoing follow up for enrolled patients.

The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833
Email: tbgoldman@arapc.com

View Map

Research Center Information: The Center for Rheumatology and Bone Research

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:  
Message:
 

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.